# A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

> **NCT01663441** · PHASE3 · COMPLETED · sponsor: **Beijing Northland Biotech. Co., Ltd.** · enrollment: 62 (actual)

## Conditions studied

- Chemotherapy-induced Thrombocytopenia

## Interventions

- **DRUG:** NL201
- **DRUG:** NL201
- **DRUG:** NL201
- **DRUG:** rhIL-11

## Key facts

- **NCT ID:** NCT01663441
- **Lead sponsor:** Beijing Northland Biotech. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01663441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01663441, "A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01663441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*